NCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
12 trialsNCT05976932 2023-08-04
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
Fudan University
Unknown
NCT05346107 2022-04-26
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT04348032 2022-03-31
APPROVE
ChineseAMS
Phase 2 Unknown
NCT04887961 2021-08-09
MITO36
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT03268772 2020-04-22
PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS
Fudan University
Phase 2 Unknown
NCT03952572 2019-05-16
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
Peking University
Phase 3 Unknown
NCT03949634 2019-05-14
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)
Fudan University
Phase 3 Unknown
NCT03446495 2018-02-26
Renaissance
Scientific Medical Society, Kazakhstan
Unknown
NCT03419494 2018-02-05
Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Unknown
NCT01051362 2010-01-18
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown